Direct oral anticoagulants for the treatment of acute venous thromboembolism in patients with cancer: a meta-analysis of randomised controlled trials
Venous thromboembolism (VTE) is a common complication in cancer patients [1, 2], associated with an 8–10% annual bleeding risk during anticoagulant therapy and a 10–20% annual risk of VTE recurrence [1, 3].
Source: European Respiratory Journal - Category: Respiratory Medicine Authors: Di Minno, M. N. D., Ageno, W., Lupoli, R., Conte, G., van Es, N., Buller, H. R., Dentali, F. Tags: Pulmonary vascular disease Original Articles: Research letters Source Type: research
More News: Bleeding | Cancer | Cancer & Oncology | Oral Cancer | Pulmonary Thromboembolism | Respiratory Medicine | Thrombosis